Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.
Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.
复制标题
DOI：
10.1155/2013/963748
复制
发表时间：
2013
影响因子：
4.6
通讯作者：
Buc M
中科院分区：
文献类型：
--
作者：
Buc M
多发性硬化症 (MS) 是一种炎症性疾病，大脑和脊髓轴突周围的髓鞘受损，导致脱髓鞘和疤痕以及广泛的体征和症状。它是由未知环境因素诱导的遗传易感个体对自身抗原的自身免疫反应引起的。免疫系统中驱动免疫病理过程的主要细胞是 T 细胞，尤其是 TH1 和 TH17 亚群。然而，近年来，有报道称调节性T细胞也参与其中。随后，人们努力寻找重建其生理功能的方法。在这篇综述中，我们描述了当代和新兴 MS 免疫治疗药物对 Treg 细胞和参与疾病免疫发病机制的其他免疫系统细胞的已知作用机制、功效和副作用。此外，我们还讨论了实验室免疫学如何为医生提供诊断过程和决定应使用哪种生物疗法的帮助。
Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms. It is caused by an autoimmune response to self-antigens in a genetically susceptible individual induced by unknown environmental factors. Principal cells of the immune system that drive the immunopathological processes are T cells, especially of TH1 and TH17 subsets. However, in recent years, it was disclosed that regulatory T cells took part in, too. Subsequently, there was endeavour to develop ways how to re-establish their physiological functions. In this review, we describe known mechanisms of action, efficacy, and side-effects of contemporary and emerging MS immunotherapeutical agents on Treg cells and other cells of the immune system involved in the immunopathogenesis of the disease. Furthermore, we discuss how laboratory immunology can offer physicians its help in the diagnosis process and decisions what kind of biological therapy should be used.
登录
查看更多内容
影响因子：
15.3
作者：
Bayer, AL;Yu, AX;Adeegbe, D;Malek, TR
通讯作者：
Malek, TR
影响因子：
168.9
作者：
Coles, AJ;Wing, N;Compston, A
通讯作者：
Compston, A
影响因子：
1.9
作者：
Graber, J. J.;McGraw, C. A.;Dhib-Jalbut, S.
通讯作者：
Dhib-Jalbut, S.
影响因子：
3.3
作者：
Chen, Meiyue;Chen, Guangjie;Hong, Jian
通讯作者：
Hong, Jian
影响因子：
82.9
作者：
Genain, CP;Cannella, B;Raine, CS
通讯作者：
Raine, CS